title: The role of targeted therapies in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.
abstract: OBJECTIVE
  What is the influence of targeted medical therapies on disease control and survival in the adult patient with progressive glioblastoma?
  
  
  METHODS
  This recommendation applies to adult patients with progressive glioblastoma
  
  
  CONCLUSIONS
  Level III Treatment with bevacizumab is recommended as it provides improved disease control compared to historical controls as measured by best imaging response and progression free survival at 6 months. Given that there are a large number of therapies are available for progressive glioblastoma that may be applied under selected circumstances dependent on patient characteristics and treating physician judgment, it is strongly recommended that patients with progressive glioblastoma be enrolled in properly designed clinical investigations to provide convincing evidence of therapeutic value.
authors.affiliation: Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA, jolson@emory.edu.
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Olson
authors.forename: Lakshmi
authors.initials: L
authors.lastname: Nayak
authors.forename: D Ryan
authors.initials: DR
authors.lastname: Ormond
authors.forename: Patrick Y
authors.initials: PY
authors.lastname: Wen
authors.forename: Steven N
authors.initials: SN
authors.lastname: Kalkanis
authors.forename: Timothy Charles
authors.initials: TC
authors.lastname: Ryken
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D018450:Disease Progression; D018572:Disease-Free Survival; D016503:Drug Delivery Systems / Q000379:methods; D019317:Evidence-Based Medicine; D005909:Glioblastoma / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D058990:Molecular Targeted Therapy
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab
references.citation: Clin Cancer Res. 2007 Feb 15;13(4):1253-9
references.pmid: 17317837
references.citation: Clin Cancer Res. 2012 Apr 15;18(8):2199-209
references.pmid: 22407828
references.citation: J Cancer Res Clin Oncol. 2011 Feb;137(2):287-93
references.pmid: 20401670
references.citation: J Neurooncol. 2011 Nov;105(2):375-81
references.pmid: 21547395
references.citation: J Clin Oncol. 1999 Aug;17(8):2572-8
references.pmid: 10561324
references.citation: Curr Oncol. 2011 Jun;18(3):e126-36
references.pmid: 21655151
references.citation: Clin Cancer Res. 1996 Apr;2(4):619-22
references.pmid: 9816211
references.citation: Chin Med J (Engl). 2009 Jun 5;122(11):1250-4
references.pmid: 19567132
references.citation: J Clin Oncol. 2009 Oct 1;27(28):4733-40
references.pmid: 19720927
references.citation: J Neurooncol. 2001 Jan;51(1):41-5
references.pmid: 11349879
references.citation: J Neurooncol. 2003 May;63(1):81-6
references.pmid: 12814259
references.citation: J Neurooncol. 2011 Apr;102(2):273-80
references.pmid: 20652724
references.citation: Clin Cancer Res. 2000 Jan;6(1):102-11
references.pmid: 10656438
references.citation: Oncologist. 2009 Nov;14(11):1131-8
references.pmid: 19897538
references.citation: J Clin Oncol. 2008 Dec 1;26(34):5610-7
references.pmid: 18981465
references.citation: J Clin Oncol. 2007 Oct 20;25(30):4722-9
references.pmid: 17947719
references.citation: Cancer. 2004 Mar 15;100(6):1199-207
references.pmid: 15022287
references.citation: Cancer. 2011 Dec 1;117(23):5351-8
references.pmid: 21590689
references.citation: Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6242-4
references.pmid: 10841526
references.citation: Neuro Oncol. 2009 Oct;11(5):550-5
references.pmid: 19332770
references.citation: Br J Cancer. 2007 Apr 10;96(7):1047-51
references.pmid: 17353924
references.citation: Cancer. 2012 Apr 15;118(8):2163-72
references.pmid: 21882183
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1168-74
references.pmid: 20124186
references.citation: N Engl J Med. 2012 Jun 28;366(26):2455-65
references.pmid: 22658128
references.citation: J Neurooncol. 2001 Aug;54(1):31-8
references.pmid: 11763420
references.citation: Clin Cancer Res. 2011 Jan 1;17(1):6-11
references.pmid: 21208902
references.citation: J Neurooncol. 1996 Feb;27(2):149-55
references.pmid: 8699237
references.citation: Cancer. 2003 May 1;97(9 Suppl):2381-6
references.pmid: 12712460
references.citation: J Neurooncol. 1999 May;43(1):79-86
references.pmid: 10448875
references.citation: J Clin Oncol. 1999 Mar;17(3):984-90
references.pmid: 10071293
references.citation: Anticancer Res. 2010 Dec;30(12):5213-6
references.pmid: 21187515
references.citation: J Neurooncol. 1997 Sep;34(2):145-51
references.pmid: 9210061
references.citation: J Neurooncol. 1998 Apr;37(2):169-76
references.pmid: 9524096
references.citation: J Clin Oncol. 2004 Nov 1;22(21):4282-9
references.pmid: 15514370
references.citation: World Neurosurg. 2012 Jan;77(1):130-4
references.pmid: 22405392
references.citation: Hum Gene Ther. 2012 Oct;23(10):1043-53
references.pmid: 22780919
references.citation: Neurosurgery. 1992 Jun;30(6):897-902; discussion 902-3
references.pmid: 1377370
references.citation: Cancer Res. 2006 Aug 15;66(16):8109-15
references.pmid: 16912188
references.citation: Cell. 1996 Aug 9;86(3):353-64
references.pmid: 8756718
references.citation: J Neurooncol. 2008 Sep;89(2):211-8
references.pmid: 18458820
references.citation: Trends Mol Med. 2009 Nov;15(11):519-30
references.pmid: 19889578
references.citation: Cancer. 1989 Dec 15;64(12):2420-3
references.pmid: 2555038
references.citation: Neurology. 2006 Jul 11;67(1):156-8
references.pmid: 16832099
references.citation: Clin Cancer Res. 2009 Dec 15;15(24):7471-7478
references.pmid: 20008847
references.citation: Neuro Oncol. 2003 Apr;5(2):96-103
references.pmid: 12672281
references.citation: J Neurooncol. 2012 Mar;107(1):155-64
references.pmid: 21986722
references.citation: Glia. 1995 Nov;15(3):339-47
references.pmid: 8586468
references.citation: Neuro Oncol. 2010 Aug;12(8):871-81
references.pmid: 20511192
references.citation: J Clin Oncol. 1999 May;17(5):1516-25
references.pmid: 10334539
references.citation: Ann Oncol. 2005 Oct;16(10):1702-8
references.pmid: 16033874
references.citation: Clin Cancer Res. 1999 Oct;5(10):2963-70
references.pmid: 10537366
references.citation: J Neurooncol. 2009 May;93(1):1-23
references.pmid: 19430879
references.citation: Ann Oncol. 2003 Apr;14(4):603-14
references.pmid: 12649109
references.citation: J Neurooncol. 2006 Jul;78(3):311-6
references.pmid: 16710748
references.citation: J Clin Oncol. 2004 Jan 1;22(1):133-42
references.pmid: 14638850
references.citation: CNS Neurol Disord Drug Targets. 2009 Jun;8(3):184-94
references.pmid: 19601816
references.citation: J Clin Oncol. 1999 Feb;17(2):645-50
references.pmid: 10080610
references.citation: J Neurooncol. 2006 May;78(1):85-90
references.pmid: 16391896
references.citation: J Neurooncol. 1997 Sep;34(2):193-200
references.pmid: 9210068
references.citation: Neuro Oncol. 2011 Jan;13(1):132-42
references.pmid: 20980335
references.citation: Neuro Oncol. 2010 Jan;12(1):95-103
references.pmid: 20150372
references.citation: Nat Rev Cancer. 2008 Aug;8(8):592-603
references.pmid: 18650835
references.citation: Cancer Cell. 2004 Nov;6(5):507-16
references.pmid: 15542434
references.citation: J Neurooncol. 2009 Apr;92(2):149-55
references.pmid: 19043778
references.citation: Br J Cancer. 2009 Dec 15;101(12):1986-94
references.pmid: 19920819
references.citation: J Neurooncol. 2008 Sep;89(3):255-8
references.pmid: 18498002
references.citation: Invest New Drugs. 2005 Aug;23(4):357-61
references.pmid: 16012795
references.citation: Expert Rev Neurother. 2011 Oct;11(10):1399-409
references.pmid: 21955197
references.citation: PLoS One. 2009 Nov 13;4(11):e7752
references.pmid: 19915670
references.citation: J Neurooncol. 2007 Feb;81(3):271-7
references.pmid: 17031561
references.citation: J Neurooncol. 2009 Sep;94(3):373-82
references.pmid: 19387557
references.citation: Neuro Oncol. 2007 Jan;9(1):29-38
references.pmid: 17108063
references.citation: Clin Cancer Res. 2007 Apr 1;13(7):2158-67
references.pmid: 17404100
references.citation: J Neurooncol. 1997 Mar;32(1):45-55
references.pmid: 9049862
references.citation: Neuro Oncol. 2006 Apr;8(2):189-93
references.pmid: 16533878
references.citation: J Neurooncol. 2010 Jan;96(2):259-69
references.pmid: 19593660
references.citation: J Neurooncol. 2005 Aug;74(1):77-86
references.pmid: 16078112
references.citation: Cancer Invest. 2002;20(7-8):948-54
references.pmid: 12449727
references.citation: Clin Dev Immunol. 2011;2011:732413
references.pmid: 22190972
references.citation: J Neurooncol. 2012 Jan;106(1):147-53
references.pmid: 21739168
references.citation: J Clin Oncol. 2008 Feb 20;26(6):1012-3; author reply 1013
references.pmid: 18281677
references.citation: Neuro Oncol. 2012 Feb;14(2):215-21
references.pmid: 22090453
references.citation: J Neurooncol. 2010 Jan;96(2):219-30
references.pmid: 19562254
references.citation: Semin Oncol. 2003 Dec;30(6 Suppl 19):10-4
references.pmid: 14765378
references.citation: Neuro Oncol. 2007 Jul;9(3):354-63
references.pmid: 17452651
references.citation: J Neurooncol. 2011 Jan;101(1):57-66
references.pmid: 20443129
references.citation: Cancer Res. 2006 Aug 15;66(16):7843-8
references.pmid: 16912155
references.citation: Integr Cancer Ther. 2006 Mar;5(1):40-7
references.pmid: 16484713
references.citation: J Clin Oncol. 2009 Feb 10;27(5):740-5
references.pmid: 19114704
references.citation: Cancer. 2012 Mar 1;118(5):1302-12
references.pmid: 21792866
references.citation: Cancer Res. 2005 Aug 15;65(16):7462-9
references.pmid: 16103100
references.citation: J Clin Oncol. 2005 Aug 10;23(23):5294-304
references.pmid: 15998902
references.citation: Science. 2006 May 26;312(5777):1171-5
references.pmid: 16728631
references.citation: Clin Cancer Res. 1996 Dec;2(12):1931-5
references.pmid: 9816151
references.citation: J Immunol. 1989 Nov 15;143(10):3222-9
references.pmid: 2809198
references.citation: J Neurooncol. 2000;46(3):249-59
references.pmid: 10902856
references.citation: J Clin Oncol. 2009 Apr 20;27(12):2052-8
references.pmid: 19307505
references.citation: J Neurooncol. 2012 Mar;107(1):207-12
references.pmid: 21984115
references.citation: Neuro Oncol. 2012 Jan;14(1):93-100
references.pmid: 22028388
references.citation: Clin Cancer Res. 2010 Nov 1;16(21):5296-302
references.pmid: 20837695
references.citation: J Clin Oncol. 2008 Oct 1;26(28):4659-65
references.pmid: 18824712
references.citation: J Clin Oncol. 2011 Jul 1;29(19):2689-95
references.pmid: 21606416
references.citation: J Clin Oncol. 2001 Jul 1;19(13):3260-6
references.pmid: 11432894
references.citation: Neuro Oncol. 2008 Apr;10(2):216-22
references.pmid: 18314417
references.citation: Acta Oncol. 2009;48(1):52-8
references.pmid: 19031176
references.citation: Brain Pathol. 2005 Oct;15(4):297-310
references.pmid: 16389942
references.citation: Nat Rev Neurosci. 2007 Aug;8(8):610-22
references.pmid: 17643088
references.citation: Neuro Oncol. 2005 Jan;7(1):32-40
references.pmid: 15701280
references.citation: J Neurooncol. 2009 Feb;91(3):329-36
references.pmid: 18953493
references.citation: Nat Rev Cancer. 2010 Jan;10(1):9-22
references.pmid: 20029421
references.citation: Clin Cancer Res. 2006 Aug 15;12(16):4899-907
references.pmid: 16914578
references.citation: Neuro Oncol. 2010 Dec;12(12):1300-10
references.pmid: 20716591
references.citation: J Clin Oncol. 2006 Aug 1;24(22):3651-6
references.pmid: 16877733
references.citation: J Clin Oncol. 2005 Oct 1;23(28):6982-91
references.pmid: 16192585
references.citation: Ann Neurol. 2007 Jul;62(1):40-8
references.pmid: 17503506
references.citation: N Engl J Med. 2008 May 8;358(19):2039-49
references.pmid: 18463380
references.citation: Neuro Oncol. 2011 May;13(5):509-16
references.pmid: 21377994
references.citation: J Clin Oncol. 2003 Jun 15;21(12):2299-304
references.pmid: 12805330
references.citation: Drugs. 2010;70(2):181-9
references.pmid: 20108991
references.citation: Neuro Oncol. 2011 Apr;13(4):437-46
references.pmid: 21297127
references.citation: J Clin Oncol. 2005 Dec 20;23(36):9359-68
references.pmid: 16361636
references.citation: J Neurooncol. 2012 Apr;107(2):343-9
references.pmid: 22048878
references.citation: Nature. 2008 Oct 23;455(7216):1061-8
references.pmid: 18772890
references.citation: Surg Neurol. 2008 Sep;70(3):259-66; discussion 266-7
references.pmid: 18295834
references.citation: Neuro Oncol. 2010 May;12(5):508-16
references.pmid: 20406901
references.citation: Neuro Oncol. 2004 Jul;6(3):253-8
references.pmid: 15279718
references.citation: Annu Rev Med. 2006;57:1-18
references.pmid: 16409133
references.citation: Crit Rev Oncol Hematol. 2006 Dec;60(3):181-93
references.pmid: 16875833
references.citation: Neurology. 2008 Mar 4;70(10):779-87
references.pmid: 18316689
references.citation: Neuro Oncol. 2010 Aug;12(8):855-61
references.pmid: 20200024
references.citation: J Neurooncol. 2004 Oct;70(1):91-5
references.pmid: 15527114
references.citation: AJNR Am J Neuroradiol. 2000 Mar;21(3):471-8
references.pmid: 10730637
references.citation: J Clin Oncol. 2000 Feb;18(4):708-15
references.pmid: 10673511
references.citation: Technol Cancer Res Treat. 2006 Jun;5(3):239-50
references.pmid: 16700620
references.citation: Arch Neurol. 1999 Jun;56(6):703-8
references.pmid: 10369310
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1268-74
references.pmid: 19204207
references.citation: Nat Rev Clin Oncol. 2011 Feb;8(2):97-106
references.pmid: 21151206
references.citation: J Clin Oncol. 2003 Jun 15;21(12):2305-11
references.pmid: 12805331
references.citation: Neurology. 2006 Apr 25;66(8):1258-60
references.pmid: 16636248
references.citation: J Clin Oncol. 2010 Apr 10;28(11):1963-72
references.pmid: 20231676
references.citation: Cancer Res. 2010 Jul 1;70(13):5457-64
references.pmid: 20530668
references.citation: Nat Rev Cancer. 2003 Jun;3(6):401-10
references.pmid: 12778130
references.citation: Ann Oncol. 2001 Feb;12(2):259-66
references.pmid: 11300335
references.citation: Trends Mol Med. 2010 Sep;16(9):387-97
references.pmid: 20692206
references.citation: Br J Cancer. 2000 Sep;83(5):588-93
references.pmid: 10944597
references.citation: J Neurooncol. 2008 Aug;89(1):113-8
references.pmid: 18438609
references.citation: PLoS Comput Biol. 2012 Jan;8(1):e1002337
references.pmid: 22241976
references.citation: Cancer. 2011 Nov 1;117(21):4905-15
references.pmid: 21456013
references.citation: J Clin Oncol. 2012 Sep 10;30(26):3258-63
references.pmid: 22649140
references.citation: Neuro Oncol. 2005 Apr;7(2):177-82
references.pmid: 15831235
references.citation: J Neurooncol. 2011 Aug;104(1):287-91
references.pmid: 21153679
references.citation: Curr Opin Immunol. 2012 Apr;24(2):207-12
references.pmid: 22236695
references.citation: J Neurooncol. 2006 Jul;78(3):281-93
references.pmid: 16554966
references.citation: J Neurooncol. 2008 Oct;90(1):89-97
references.pmid: 18581057
references.citation: Clin Cancer Res. 2010 Jan 15;16(2):474-85
references.pmid: 20068073